PROSPECT provides clinicians with supporting arguments for and against the use of various interventions in postoperative pain based on published evidence and expert opinion. Clinicians must make judgments based upon the clinical circumstances and local regulations. At all times, local prescribing information for the drugs referred to must be consulted.
Total shoulder arthroplasty is frequently associated with moderate-to-severe postoperative pain (Gerbershagen 2013). A systematic review of the available evidence was therefore needed to identify and standardise effective perioperative strategies for pain management, with the aim of improving postoperative analgesia.
This review (Mrazek 2026) aimed to assess the literature and provide PROSPECT recommendations for optimal pain management after total shoulder arthroplasty.
The PROSPECT group performed the systematic review and formulated the recommendations using the unique PROSPECT methodology, available at https://esraeurope.org/prospect-methodology/. This methodology was first published in Joshi 2019 and updated in Joshi 2023.
EMBASE, MEDLINE, CENTRAL and Web of Science were searched from database inception to 2 June 2026 for randomised controlled trials (RCTs), systematic reviews, meta-analyses and umbrella reviews involving adults undergoing elective primary TSA. Eligible studies evaluated perioperative analgesic, anaesthetic or surgical interventions.
The primary outcome was postoperative pain, reported using a linear pain scale such as the Visual Analogue Scale or Numerical Rating Scale. Secondary outcomes included analgesic consumption and adverse events, where reported.
Of the studies identified by the literature search, 30 RCTs and 7 systematic reviews/meta-analyses met the inclusion criteria. The included studies were evaluated according to PROSPECT methodology. Recommendations were formulated after considering the benefits and adverse effects of the intervention in the clinical context of TSA with use of standard multimodal analgesia (paracetamol with an NSAID or COX-2-selective inhibitor).
This review is registered on PROSPERO: CRD420251156103.
In case of contraindications or absence of expertise, local infiltration analgesia (with bupivacaine or ropivacaine) is a reasonable alternative.
COX, cyclooxygenase; IV, intravenous; NSAID, non-steroidal anti-inflammatory drug; RCT, randomised controlled trial.
Analgesic interventions that are not recommended for pain management in patients undergoing primary TSA.
ISB, interscalene brachial plexus block; LIA, local infiltration analgesia.
*Non-selective NSAIDs or COX-2-selective inhibitors.
COX, cyclooxygenase; IV, intravenous; NSAID, non-steroidal anti-inflammatory drug.
PROSPECT recommendations for TSA – Infographic
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.